nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PPARG—Etoposide—Teniposide—lymphatic system cancer	0.0179	1	CbGdCrCtD
Mesalazine—Vision blurred—Carmustine—lymphatic system cancer	0.000772	0.000787	CcSEcCtD
Mesalazine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00077	0.000784	CcSEcCtD
Mesalazine—Tremor—Carmustine—lymphatic system cancer	0.000768	0.000782	CcSEcCtD
Mesalazine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000766	0.00078	CcSEcCtD
Mesalazine—Oedema—Bleomycin—lymphatic system cancer	0.000766	0.00078	CcSEcCtD
Mesalazine—Erythema—Mitoxantrone—lymphatic system cancer	0.000762	0.000776	CcSEcCtD
Mesalazine—Infection—Bleomycin—lymphatic system cancer	0.000761	0.000775	CcSEcCtD
Mesalazine—Anaemia—Carmustine—lymphatic system cancer	0.000758	0.000771	CcSEcCtD
Mesalazine—Back pain—Vincristine—lymphatic system cancer	0.000757	0.000771	CcSEcCtD
Mesalazine—Vomiting—Teniposide—lymphatic system cancer	0.000756	0.00077	CcSEcCtD
Mesalazine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00075	0.000764	CcSEcCtD
Mesalazine—Asthenia—Fludarabine—lymphatic system cancer	0.00075	0.000764	CcSEcCtD
Mesalazine—Rash—Teniposide—lymphatic system cancer	0.00075	0.000763	CcSEcCtD
Mesalazine—Dermatitis—Teniposide—lymphatic system cancer	0.000749	0.000763	CcSEcCtD
Mesalazine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000746	0.00076	CcSEcCtD
Mesalazine—Headache—Teniposide—lymphatic system cancer	0.000745	0.000759	CcSEcCtD
Mesalazine—Pruritus—Fludarabine—lymphatic system cancer	0.000739	0.000753	CcSEcCtD
Mesalazine—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000739	0.000752	CcSEcCtD
Mesalazine—Back pain—Mitoxantrone—lymphatic system cancer	0.000737	0.00075	CcSEcCtD
Mesalazine—Leukopenia—Carmustine—lymphatic system cancer	0.000734	0.000747	CcSEcCtD
Mesalazine—Anorexia—Bleomycin—lymphatic system cancer	0.00073	0.000744	CcSEcCtD
Mesalazine—Anaemia—Vincristine—lymphatic system cancer	0.000723	0.000736	CcSEcCtD
Mesalazine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000718	0.000731	CcSEcCtD
Mesalazine—Photosensitivity—Methotrexate—lymphatic system cancer	0.000718	0.000731	CcSEcCtD
Mesalazine—Hypotension—Bleomycin—lymphatic system cancer	0.000716	0.000729	CcSEcCtD
Mesalazine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000715	0.000728	CcSEcCtD
Mesalazine—Hypertension—Carmustine—lymphatic system cancer	0.000708	0.000721	CcSEcCtD
Mesalazine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000707	0.00072	CcSEcCtD
Mesalazine—Nausea—Teniposide—lymphatic system cancer	0.000706	0.000719	CcSEcCtD
Mesalazine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000704	0.000717	CcSEcCtD
Mesalazine—Vertigo—Vincristine—lymphatic system cancer	0.000703	0.000716	CcSEcCtD
Mesalazine—Hepatic failure—Methotrexate—lymphatic system cancer	0.000701	0.000714	CcSEcCtD
Mesalazine—Leukopenia—Vincristine—lymphatic system cancer	0.0007	0.000713	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000698	0.000711	CcSEcCtD
Mesalazine—Myalgia—Carmustine—lymphatic system cancer	0.000698	0.000711	CcSEcCtD
Mesalazine—Chest pain—Carmustine—lymphatic system cancer	0.000698	0.000711	CcSEcCtD
Mesalazine—Anxiety—Carmustine—lymphatic system cancer	0.000695	0.000708	CcSEcCtD
Mesalazine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000688	0.000701	CcSEcCtD
Mesalazine—Malaise—Mitoxantrone—lymphatic system cancer	0.000687	0.0007	CcSEcCtD
Mesalazine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000683	0.000696	CcSEcCtD
Mesalazine—Renal failure acute—Methotrexate—lymphatic system cancer	0.000683	0.000695	CcSEcCtD
Mesalazine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000682	0.000694	CcSEcCtD
Mesalazine—Hypertension—Vincristine—lymphatic system cancer	0.000675	0.000688	CcSEcCtD
Mesalazine—Confusional state—Carmustine—lymphatic system cancer	0.000674	0.000687	CcSEcCtD
Mesalazine—Oedema—Carmustine—lymphatic system cancer	0.000669	0.000681	CcSEcCtD
Mesalazine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000666	0.000678	CcSEcCtD
Mesalazine—Myalgia—Vincristine—lymphatic system cancer	0.000666	0.000678	CcSEcCtD
Mesalazine—Cough—Mitoxantrone—lymphatic system cancer	0.000665	0.000677	CcSEcCtD
Mesalazine—Infection—Carmustine—lymphatic system cancer	0.000665	0.000677	CcSEcCtD
Mesalazine—Vomiting—Fludarabine—lymphatic system cancer	0.000665	0.000677	CcSEcCtD
Mesalazine—Rash—Fludarabine—lymphatic system cancer	0.000659	0.000671	CcSEcCtD
Mesalazine—Dermatitis—Fludarabine—lymphatic system cancer	0.000658	0.00067	CcSEcCtD
Mesalazine—Hypertension—Mitoxantrone—lymphatic system cancer	0.000658	0.00067	CcSEcCtD
Mesalazine—Pain—Bleomycin—lymphatic system cancer	0.000655	0.000667	CcSEcCtD
Mesalazine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000655	0.000667	CcSEcCtD
Mesalazine—Headache—Fludarabine—lymphatic system cancer	0.000655	0.000667	CcSEcCtD
Mesalazine—Tachycardia—Carmustine—lymphatic system cancer	0.000653	0.000665	CcSEcCtD
Mesalazine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000649	0.000661	CcSEcCtD
Mesalazine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000649	0.000661	CcSEcCtD
Mesalazine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000649	0.000661	CcSEcCtD
Mesalazine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000646	0.000658	CcSEcCtD
Mesalazine—Lethargy—Methotrexate—lymphatic system cancer	0.000643	0.000655	CcSEcCtD
Mesalazine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000641	0.000653	CcSEcCtD
Mesalazine—Oedema—Vincristine—lymphatic system cancer	0.000639	0.00065	CcSEcCtD
Mesalazine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000639	0.00065	CcSEcCtD
Mesalazine—Anorexia—Carmustine—lymphatic system cancer	0.000638	0.000649	CcSEcCtD
Mesalazine—Infection—Vincristine—lymphatic system cancer	0.000634	0.000646	CcSEcCtD
Mesalazine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000631	0.000643	CcSEcCtD
Mesalazine—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00063	0.000642	CcSEcCtD
Mesalazine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000627	0.000638	CcSEcCtD
Mesalazine—Nervous system disorder—Vincristine—lymphatic system cancer	0.000626	0.000638	CcSEcCtD
Mesalazine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000625	0.000637	CcSEcCtD
Mesalazine—Hypotension—Carmustine—lymphatic system cancer	0.000625	0.000636	CcSEcCtD
Mesalazine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000622	0.000633	CcSEcCtD
Mesalazine—Oedema—Mitoxantrone—lymphatic system cancer	0.000622	0.000633	CcSEcCtD
Mesalazine—Nausea—Fludarabine—lymphatic system cancer	0.000621	0.000632	CcSEcCtD
Mesalazine—Infection—Mitoxantrone—lymphatic system cancer	0.000618	0.000629	CcSEcCtD
Mesalazine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000617	0.000629	CcSEcCtD
Mesalazine—Shock—Mitoxantrone—lymphatic system cancer	0.000612	0.000623	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000609	0.000621	CcSEcCtD
Mesalazine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000609	0.00062	CcSEcCtD
Mesalazine—Urticaria—Bleomycin—lymphatic system cancer	0.000609	0.00062	CcSEcCtD
Mesalazine—Anorexia—Vincristine—lymphatic system cancer	0.000609	0.00062	CcSEcCtD
Mesalazine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000607	0.000618	CcSEcCtD
Mesalazine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000606	0.000617	CcSEcCtD
Mesalazine—Insomnia—Carmustine—lymphatic system cancer	0.000605	0.000616	CcSEcCtD
Mesalazine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000604	0.000615	CcSEcCtD
Mesalazine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000601	0.000612	CcSEcCtD
Mesalazine—Paraesthesia—Carmustine—lymphatic system cancer	0.000601	0.000612	CcSEcCtD
Mesalazine—Mood swings—Methotrexate—lymphatic system cancer	0.000597	0.000608	CcSEcCtD
Mesalazine—Hypotension—Vincristine—lymphatic system cancer	0.000597	0.000608	CcSEcCtD
Mesalazine—Dyspnoea—Carmustine—lymphatic system cancer	0.000596	0.000607	CcSEcCtD
Mesalazine—Somnolence—Carmustine—lymphatic system cancer	0.000595	0.000606	CcSEcCtD
Mesalazine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000593	0.000604	CcSEcCtD
Mesalazine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000582	0.000593	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000582	0.000592	CcSEcCtD
Mesalazine—Decreased appetite—Carmustine—lymphatic system cancer	0.000581	0.000592	CcSEcCtD
Mesalazine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000581	0.000592	CcSEcCtD
Mesalazine—Insomnia—Vincristine—lymphatic system cancer	0.000578	0.000588	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000577	0.000588	CcSEcCtD
Mesalazine—Paraesthesia—Vincristine—lymphatic system cancer	0.000573	0.000584	CcSEcCtD
Mesalazine—Pain—Carmustine—lymphatic system cancer	0.000572	0.000582	CcSEcCtD
Mesalazine—Constipation—Carmustine—lymphatic system cancer	0.000572	0.000582	CcSEcCtD
Mesalazine—Breast disorder—Methotrexate—lymphatic system cancer	0.00057	0.00058	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000567	0.000577	CcSEcCtD
Mesalazine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000565	0.000575	CcSEcCtD
Mesalazine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000558	0.000569	CcSEcCtD
Mesalazine—Decreased appetite—Vincristine—lymphatic system cancer	0.000555	0.000565	CcSEcCtD
Mesalazine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000554	0.000565	CcSEcCtD
Mesalazine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000553	0.000563	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000551	0.000561	CcSEcCtD
Mesalazine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000551	0.000561	CcSEcCtD
Mesalazine—Fatigue—Vincristine—lymphatic system cancer	0.000551	0.000561	CcSEcCtD
Mesalazine—Asthenia—Bleomycin—lymphatic system cancer	0.00055	0.00056	CcSEcCtD
Mesalazine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000547	0.000557	CcSEcCtD
Mesalazine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000547	0.000557	CcSEcCtD
Mesalazine—Pain—Vincristine—lymphatic system cancer	0.000546	0.000556	CcSEcCtD
Mesalazine—Constipation—Vincristine—lymphatic system cancer	0.000546	0.000556	CcSEcCtD
Mesalazine—Asthma—Methotrexate—lymphatic system cancer	0.000545	0.000555	CcSEcCtD
Mesalazine—Pruritus—Bleomycin—lymphatic system cancer	0.000542	0.000552	CcSEcCtD
Mesalazine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000541	0.00055	CcSEcCtD
Mesalazine—Eosinophilia—Methotrexate—lymphatic system cancer	0.000539	0.000549	CcSEcCtD
Mesalazine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000536	0.000546	CcSEcCtD
Mesalazine—Pancreatitis—Methotrexate—lymphatic system cancer	0.000534	0.000544	CcSEcCtD
Mesalazine—Pain—Mitoxantrone—lymphatic system cancer	0.000532	0.000541	CcSEcCtD
Mesalazine—Constipation—Mitoxantrone—lymphatic system cancer	0.000532	0.000541	CcSEcCtD
Mesalazine—Abdominal pain—Carmustine—lymphatic system cancer	0.000529	0.000538	CcSEcCtD
Mesalazine—Body temperature increased—Carmustine—lymphatic system cancer	0.000529	0.000538	CcSEcCtD
Mesalazine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000522	0.000532	CcSEcCtD
Mesalazine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000522	0.000532	CcSEcCtD
Mesalazine—Pancytopenia—Methotrexate—lymphatic system cancer	0.000517	0.000527	CcSEcCtD
Mesalazine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000512	0.000522	CcSEcCtD
Mesalazine—Dysuria—Methotrexate—lymphatic system cancer	0.000509	0.000519	CcSEcCtD
Mesalazine—Neutropenia—Methotrexate—lymphatic system cancer	0.000509	0.000519	CcSEcCtD
Mesalazine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000509	0.000518	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000506	0.000516	CcSEcCtD
Mesalazine—Abdominal pain—Vincristine—lymphatic system cancer	0.000505	0.000514	CcSEcCtD
Mesalazine—Body temperature increased—Vincristine—lymphatic system cancer	0.000505	0.000514	CcSEcCtD
Mesalazine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000497	0.000506	CcSEcCtD
Mesalazine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000494	0.000503	CcSEcCtD
Mesalazine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000493	0.000502	CcSEcCtD
Mesalazine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000492	0.000501	CcSEcCtD
Mesalazine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000492	0.000501	CcSEcCtD
Mesalazine—Pneumonia—Methotrexate—lymphatic system cancer	0.000489	0.000498	CcSEcCtD
Mesalazine—Vomiting—Bleomycin—lymphatic system cancer	0.000487	0.000496	CcSEcCtD
Mesalazine—Infestation NOS—Methotrexate—lymphatic system cancer	0.000486	0.000495	CcSEcCtD
Mesalazine—Infestation—Methotrexate—lymphatic system cancer	0.000486	0.000495	CcSEcCtD
Mesalazine—Depression—Methotrexate—lymphatic system cancer	0.000484	0.000493	CcSEcCtD
Mesalazine—Rash—Bleomycin—lymphatic system cancer	0.000483	0.000492	CcSEcCtD
Mesalazine—Dermatitis—Bleomycin—lymphatic system cancer	0.000483	0.000492	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000482	0.00049	CcSEcCtD
Mesalazine—Asthenia—Carmustine—lymphatic system cancer	0.00048	0.000489	CcSEcCtD
Mesalazine—Renal failure—Methotrexate—lymphatic system cancer	0.000478	0.000486	CcSEcCtD
Mesalazine—Stomatitis—Methotrexate—lymphatic system cancer	0.000474	0.000482	CcSEcCtD
Mesalazine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000472	0.000481	CcSEcCtD
Mesalazine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00047	0.000479	CcSEcCtD
Mesalazine—Sweating—Methotrexate—lymphatic system cancer	0.000466	0.000474	CcSEcCtD
Mesalazine—Haematuria—Methotrexate—lymphatic system cancer	0.000463	0.000472	CcSEcCtD
Mesalazine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000459	0.000468	CcSEcCtD
Mesalazine—Epistaxis—Methotrexate—lymphatic system cancer	0.000458	0.000467	CcSEcCtD
Mesalazine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000458	0.000467	CcSEcCtD
Mesalazine—Asthenia—Vincristine—lymphatic system cancer	0.000458	0.000466	CcSEcCtD
Mesalazine—Diarrhoea—Carmustine—lymphatic system cancer	0.000458	0.000466	CcSEcCtD
Mesalazine—Nausea—Bleomycin—lymphatic system cancer	0.000455	0.000463	CcSEcCtD
Mesalazine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000453	0.000462	CcSEcCtD
Mesalazine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000446	0.000454	CcSEcCtD
Mesalazine—Dizziness—Carmustine—lymphatic system cancer	0.000442	0.00045	CcSEcCtD
Mesalazine—Haemoglobin—Methotrexate—lymphatic system cancer	0.000438	0.000446	CcSEcCtD
Mesalazine—Diarrhoea—Vincristine—lymphatic system cancer	0.000437	0.000445	CcSEcCtD
Mesalazine—Haemorrhage—Methotrexate—lymphatic system cancer	0.000436	0.000444	CcSEcCtD
Mesalazine—Hepatitis—Methotrexate—lymphatic system cancer	0.000436	0.000444	CcSEcCtD
Mesalazine—Pharyngitis—Methotrexate—lymphatic system cancer	0.000433	0.000441	CcSEcCtD
Mesalazine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000431	0.000439	CcSEcCtD
Mesalazine—Urethral disorder—Methotrexate—lymphatic system cancer	0.000427	0.000435	CcSEcCtD
Mesalazine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000425	0.000433	CcSEcCtD
Mesalazine—Vomiting—Carmustine—lymphatic system cancer	0.000425	0.000433	CcSEcCtD
Mesalazine—Dizziness—Vincristine—lymphatic system cancer	0.000422	0.00043	CcSEcCtD
Mesalazine—Rash—Carmustine—lymphatic system cancer	0.000422	0.000429	CcSEcCtD
Mesalazine—Dermatitis—Carmustine—lymphatic system cancer	0.000421	0.000429	CcSEcCtD
Mesalazine—Headache—Carmustine—lymphatic system cancer	0.000419	0.000427	CcSEcCtD
Mesalazine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000412	0.00042	CcSEcCtD
Mesalazine—Eye disorder—Methotrexate—lymphatic system cancer	0.000408	0.000415	CcSEcCtD
Mesalazine—Tinnitus—Methotrexate—lymphatic system cancer	0.000407	0.000414	CcSEcCtD
Mesalazine—Vomiting—Vincristine—lymphatic system cancer	0.000406	0.000413	CcSEcCtD
Mesalazine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000405	0.000412	CcSEcCtD
Mesalazine—Rash—Vincristine—lymphatic system cancer	0.000403	0.00041	CcSEcCtD
Mesalazine—Dermatitis—Vincristine—lymphatic system cancer	0.000402	0.00041	CcSEcCtD
Mesalazine—Headache—Vincristine—lymphatic system cancer	0.0004	0.000407	CcSEcCtD
Mesalazine—Nausea—Carmustine—lymphatic system cancer	0.000397	0.000405	CcSEcCtD
Mesalazine—Angiopathy—Methotrexate—lymphatic system cancer	0.000396	0.000403	CcSEcCtD
Mesalazine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000395	0.000403	CcSEcCtD
Mesalazine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000394	0.000401	CcSEcCtD
Mesalazine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000393	0.0004	CcSEcCtD
Mesalazine—Rash—Mitoxantrone—lymphatic system cancer	0.000392	0.000399	CcSEcCtD
Mesalazine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000392	0.000399	CcSEcCtD
Mesalazine—Chills—Methotrexate—lymphatic system cancer	0.000391	0.000398	CcSEcCtD
Mesalazine—Headache—Mitoxantrone—lymphatic system cancer	0.00039	0.000397	CcSEcCtD
Mesalazine—Alopecia—Methotrexate—lymphatic system cancer	0.000385	0.000392	CcSEcCtD
Mesalazine—Mental disorder—Methotrexate—lymphatic system cancer	0.000382	0.000389	CcSEcCtD
Mesalazine—Erythema—Methotrexate—lymphatic system cancer	0.00038	0.000387	CcSEcCtD
Mesalazine—Nausea—Vincristine—lymphatic system cancer	0.000379	0.000386	CcSEcCtD
Mesalazine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000372	0.000379	CcSEcCtD
Mesalazine—Nausea—Mitoxantrone—lymphatic system cancer	0.000369	0.000376	CcSEcCtD
Mesalazine—Back pain—Methotrexate—lymphatic system cancer	0.000367	0.000374	CcSEcCtD
Mesalazine—Vision blurred—Methotrexate—lymphatic system cancer	0.000358	0.000364	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000352	0.000359	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—lymphatic system cancer	0.000351	0.000357	CcSEcCtD
Mesalazine—Malaise—Methotrexate—lymphatic system cancer	0.000342	0.000349	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—lymphatic system cancer	0.000341	0.000347	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—lymphatic system cancer	0.00034	0.000346	CcSEcCtD
Mesalazine—Cough—Methotrexate—lymphatic system cancer	0.000331	0.000337	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—lymphatic system cancer	0.000323	0.000329	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—lymphatic system cancer	0.000323	0.000329	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—lymphatic system cancer	0.000323	0.000329	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000321	0.000327	CcSEcCtD
Mesalazine—Discomfort—Methotrexate—lymphatic system cancer	0.000319	0.000325	CcSEcCtD
Mesalazine—Confusional state—Methotrexate—lymphatic system cancer	0.000312	0.000318	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00031	0.000315	CcSEcCtD
Mesalazine—Infection—Methotrexate—lymphatic system cancer	0.000308	0.000313	CcSEcCtD
Mesalazine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000304	0.000309	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000303	0.000309	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—lymphatic system cancer	0.000301	0.000306	CcSEcCtD
Mesalazine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.0003	0.000305	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—lymphatic system cancer	0.000295	0.000301	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—lymphatic system cancer	0.00029	0.000295	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000282	0.000287	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—lymphatic system cancer	0.00028	0.000285	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000278	0.000283	CcSEcCtD
Mesalazine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000276	0.000281	CcSEcCtD
Mesalazine—Somnolence—Methotrexate—lymphatic system cancer	0.000275	0.00028	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000273	0.000278	CcSEcCtD
Mesalazine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000269	0.000274	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000267	0.000272	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—lymphatic system cancer	0.000267	0.000272	CcSEcCtD
Mesalazine—Pain—Methotrexate—lymphatic system cancer	0.000265	0.00027	CcSEcCtD
Mesalazine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000255	0.00026	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000253	0.000258	CcSEcCtD
Mesalazine—Urticaria—Methotrexate—lymphatic system cancer	0.000246	0.000251	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000245	0.000249	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000245	0.000249	CcSEcCtD
Mesalazine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000228	0.000232	CcSEcCtD
Mesalazine—Asthenia—Methotrexate—lymphatic system cancer	0.000222	0.000226	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—lymphatic system cancer	0.000219	0.000223	CcSEcCtD
Mesalazine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000212	0.000216	CcSEcCtD
Mesalazine—Dizziness—Methotrexate—lymphatic system cancer	0.000205	0.000209	CcSEcCtD
Mesalazine—Vomiting—Methotrexate—lymphatic system cancer	0.000197	0.000201	CcSEcCtD
Mesalazine—Rash—Methotrexate—lymphatic system cancer	0.000195	0.000199	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—lymphatic system cancer	0.000195	0.000199	CcSEcCtD
Mesalazine—Headache—Methotrexate—lymphatic system cancer	0.000194	0.000198	CcSEcCtD
Mesalazine—Nausea—Methotrexate—lymphatic system cancer	0.000184	0.000187	CcSEcCtD
